|
5 May 2025 | ACB News ImpediMed Limited (ASX: IPD) has reported record financial results for Q3 FY25, with revenue reaching A$3.4 million (+28% YoY), cash receipts at A$4.1 million, and ARR rising to A$13.7 million (+27% YoY). Total Contracted Value (TCV) hit A$4.9 million, up 53% from the previous quarter. The company signed key renewals across U.S. NCCN centers and IDNs, achieving a 19% average uplift in pricing. Over 500 new sales leads were identified, with commercial deployments advancing across 28 IDNs. The SOZO® Pro device is undergoing clinical validation in heart failure and other indications. To mitigate supply chain risks, ImpediMed will make a A$1.2 million payment in Q4 to secure critical components. FY25 operating costs are forecast to be 10% lower than FY24. Shares rebounded last week after retesting the A$0.03 level, a key low first established in 2020, and reached an intraday high of A$0.042 on rising trading volume. Key watchpoints include recurring revenue momentum, U.S. market execution, and progress in new clinical indications that could support a future re-rating. |
 |
